Cited by 2,020Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisOccupational and environmental lung diseasesPulmonary Hypertension Research and Treatments

The DOI matches its Crossref record; 141 of the 143 references it cites were found in a registry or an index.

Idiopathic pulmonary fibrosis

Richeldi, Luca, Collard, Harold R, Jones, Mark G·2017·The Lancet

DOI 10.1016/s0140-6736(17)30866-8

Open this paper in CoChat — free account

Abstract

Idiopathic pulmonary fibrosis is a prototype of chronic, progressive, and fibrotic lung disease. Healthy tissue is replaced by altered extracellular matrix and alveolar architecture is destroyed, which leads to decreased lung compliance, disrupted gas exchange, and ultimately respiratory failure and death. In less than a decade, understanding of the pathogenesis and management of this disease has been transformed, and two disease-modifying therapies have been approved, worldwide. In this Seminar, we summarise the presentation, pathophysiology, diagnosis, and treatment options available for patients with idiopathic pulmonary fibrosis. This disease has improved understanding of the mechanisms of lung fibrosis, and offers hope that similar approaches will transform the management of patients with other progressive fibrotic lung diseases.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(17)30866-8

Cites

141 of 141 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cancer Incidence in Five Continents
Doll, R., Muir, C. S., & Waterhouse, J. A. H. (1970) · Springer eBooks · doi:10.1007/978-3-642-85851-2 · Cited by 8,485
An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citation
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
Self-citation
An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias
Travis, W. D., Costabel, U., Hansell, D. M., King, T. E., Lynch, D. A., Nicholson, A. G., Ryerson, C. J., Ryu, J. H., Selman, M., Wells, A. U., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201308-1483st · Cited by 4,378
Self-citation
American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias
(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.2.ats01 · Cited by 4,196
Fleischner Society: Glossary of Terms for Thoracic Imaging
Hansell, D. M., Bankier, A. A., MacMahon, H., McLoud, T. C., Müller, N. L., & Rémy, J. (2008) · Radiology · doi:10.1148/radiol.2462070712 · Cited by 4,189
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,651
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60405-4 · Cited by 2,154
An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis: An Update of the 2011 Clinical Practice Guideline
Raghu, G., Rochwerg, B., Zhang, Y., Garcia, C. A. C., Azuma, A., Behr, J., Brozek, J. L., Collard, H. R., Cunningham, W., Homma, S., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201506-1063st · Cited by 1,916
Self-citation

Show all 143 references

Research works printed but not linked: 1

2000, Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS), Am J Respir Crit Care Med, 161, 646, 10.1164/ajrccm.161.2.ats3-00 · DOI

Sorted by citations

Items 101–200 of 1,003

Pathogenesis of fibrostenosing Crohn's disease
Li, J., Mao, R., Kurada, S. V., Wang, J., Lin, S., Chandra, J., & Rieder, F. (2019) · Translational research · doi:10.1016/j.trsl.2019.03.005 · Cited by 103
Interleukin-11 signaling underlies fibrosis, parenchymal dysfunction, and chronic inflammation of the airway
Ng, B., Cook, S. A., & Schäfer, S. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-00531-5 · Cited by 98
Sulforaphane attenuates pulmonary fibrosis by inhibiting the epithelial-mesenchymal transition
Kyung, S. Y., Kim, D. Y., Yoon, J. Y., Son, E. S., Kim, Y. J., Park, J. W., & Jeong, S. H. (2018) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-018-0204-7 · Cited by 101
Polystyrene microplastics induce pulmonary fibrosis by promoting alveolar epithelial cell ferroptosis through cGAS/STING signaling
Zhang, J., Du, J., Liu, D., Zhuo, J., Chu, L., Li, Y., Gao, L., Xu, M., Chen, W., Huang, W., et al. (2024) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2024.116357 · Cited by 102
Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study.
Raghu, G., van den Blink, B., Hamblin, M., Brown, A., Golden, J. A., Ho, L., Wijsenbeek, M., Vašáková, M., Pesci, A., Antin-Ozerkis, D., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30172-9 · Cited by 84
Self-citation
Suppressing Sart1 to modulate macrophage polarization by siRNA-loaded liposomes: a promising therapeutic strategy for pulmonary fibrosis
Pan, T. S., Zhou, Q., Miao, K., Zhang, L., Wu, G., Yu, J., Xu, Y., Xiong, W., Li, Y., & Wang, Y. (2020) · Theranostics · doi:10.7150/thno.48152 · Cited by 101
Mitochondrial dysfunction contributes to the senescent phenotype of IPF lung fibroblasts
Schuliga, M. J., Pechkovsky, D. V., Read, J. M., Waters, D. W., Blokland, K. E. C., Reid, A. T., Hogaboam, C. M., Khalil, N., Burgess, J. K., Prêle, C. M., et al. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13855 · Cited by 98
The circadian clock protein REVERBα inhibits pulmonary fibrosis development
Cunningham, P. S., Meijer, P., Nazgiewicz, A., Anderson, S. G., Borthwick, L. A., Bagnall, J., Kitchen, G. B., Lodyga, M., Begley, N., Venkateswaran, R., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1912109117 · Cited by 97
Targeting ferroptosis as a vulnerability in pulmonary diseases
Yang, L., Cao, L., Zhang, X., & Chu, B. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05070-7 · Cited by 101
Resetting proteostasis with ISRIB promotes epithelial differentiation to attenuate pulmonary fibrosis
Watanabe, S., Markov, N. S., Lu, Z., Aillon, R. P., Soberanes, S., Runyan, C. E., Ren, Z., Grant, R. A., Maciel, M., Abdala‐Valencia, H., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2101100118 · Cited by 99
Essential involvement of the CX3CL1-CX3CR1 axis in bleomycin-induced pulmonary fibrosis via regulation of fibrocyte and M2 macrophage migration
Ishida, Y., Kimura, A., Nosaka, M., Kuninaka, Y., Hemmi, H., Sasaki, I., Kaisho, T., Mukaida, N., & Kondo, T. (2017) · Scientific Reports · doi:10.1038/s41598-017-17007-8 · Cited by 97
Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence
Richeldi, L., Varone, F., Bergna, M. A., de Andrade, J. A., Falk, J., Hallowell, R. W., Jouneau, S., Kondoh, Y., Morrow, L. E., Randerath, W. J., et al. (2018) · European Respiratory Review · doi:10.1183/16000617.0074-2018 · Cited by 99
Self-citation
Recent Progress of Ferroptosis in Lung Diseases
Yu, S., Jia, J., Zheng, J., Zhou, Y., Jia, D., & Wang, J. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.789517 · Cited by 94
lncRNA ZEB1-AS1 promotes pulmonary fibrosis through ZEB1-mediated epithelial–mesenchymal transition by competitively binding miR-141-3p
Qian, W., Cai, X., Qian, Q., Peng, W., Yu, J., Zhang, X., Tian, L., & Wang, C. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1339-1 · Cited by 93
Molecular mapping of interstitial lung disease reveals a phenotypically distinct senescent basal epithelial cell population
DePianto, D. J., Heiden, J. A. V., Morshead, K. B., Sun, K.-H., Modrusan, Z. D., Teng, G., Wolters, P. J., & Arron, J. R. (2021) · JCI Insight · doi:10.1172/jci.insight.143626 · Cited by 95
YAP/TAZ: Molecular pathway and disease therapy
Wei, Y., Hui, V. L. Z., Chen, Y., Han, R., Han, X., & Guo, Y. (2023) · MedComm · doi:10.1002/mco2.340 · Cited by 107
Molecular Mechanisms and Cellular Contribution from Lung Fibrosis to Lung Cancer Development
Samarelli, A. V., Masciale, V., Aramini, B., Coló, G. P., Tonelli, R., Marchioni, A., Bruzzi, G., Gozzi, F., Andrisani, D., Castaniere, I., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212179 · Cited by 94
The Role of TGF-β Signaling in Lung Cancer Associated with Idiopathic Pulmonary Fibrosis
Saito, A., Horie, M., Micke, P., & Nagase, T. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113611 · Cited by 94
LncRNA H19-mediated M2 polarization of macrophages promotes myofibroblast differentiation in pulmonary fibrosis induced by arsenic exposure
Xiao, T., Zou, Z., Xue, J., Syed, B. M., Sun, J., Dai, X., Shi, M., Li, J., Wei, S., Tang, H., et al. (2020) · Environmental Pollution · doi:10.1016/j.envpol.2020.115810 · Cited by 90
Metabolic requirements of pulmonary fibrosis: role of fibroblast metabolism
Hamanaka, R. B., & Mutlu, G. M. (2021) · FEBS Journal · doi:10.1111/febs.15693 · Cited by 94
Liposomes or Extracellular Vesicles: A Comprehensive Comparison of Both Lipid Bilayer Vesicles for Pulmonary Drug Delivery
Al-Jipouri, A., Almurisi, S. H., AL-Japairai, K. A. S., Bakar, L. M., & Doolaanea, A. A. (2023) · Polymers · doi:10.3390/polym15020318 · Cited by 97
Idiopathic Pulmonary Fibrosis: Epidemiology, Diagnosis andOutcomes
Wakwaya, Y. T., & Brown, K. M. (2019) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2019.02.013 · Cited by 92
Acute exacerbation of interstitial lung disease associated with rheumatic disease
Luppi, F., Sebastiani, M., Salvarani, C., Bendstrup, E. M., & Manfredi, A. (2021) · Nature Reviews Rheumatology · doi:10.1038/s41584-021-00721-z · Cited by 90
Cell Response to Mechanical Microenvironment Cues Via Rho Signaling: From Mechanobiology to Mechanomedicine
Xie, N., Xiao, C., Shu, Q., Cheng, B., Wang, Z., Xue, R., Zhang, W., Wang, J., Shi, H., Fan, D., et al. (2022) · Acta Biomaterialia · doi:10.1016/j.actbio.2023.01.039 · Cited by 90
Caveolin-1–derived peptide limits development of pulmonary fibrosis
Marudamuthu, A. S., Bhandary, Y. P., Fan, L., Radhakrishnan, V., MacKenzie, B., Maier, E., Shetty, S. K., Nagaraja, M. R., Gopu, V., Tiwari, N., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aat2848 · Cited by 86
Endothelial to mesenchymal transition (EndMT) and vascular remodeling in pulmonary hypertension and idiopathic pulmonary fibrosis
Gaikwad, A. V., Eapen, M. S., McAlinden, K. D., Chia, C., Larby, J., Myers, S., Dey, S., Haug, G., Markos, J., Glanville, A. R., et al. (2020) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2020.1795832 · Cited by 87
Nanoengineered mesenchymal stem cell therapy for pulmonary fibrosis in young and aged mice
Han, M.-M., He, X.-Y., Tang, L., Qi, L., Yang, M.-Y., Wang, Y., Xing, L., Jeong, J.-H., & Jiang, H.-L. (2023) · Science Advances · doi:10.1126/sciadv.adg5358 · Cited by 86
Targeting Degradation of the Transcription Factor C/EBPβ Reduces Lung Fibrosis by Restoring Activity of the Ubiquitin-Editing Enzyme A20 in Macrophages
Liu, S.-S., Lv, X.-X., Liu, C., Qi, J., Li, Y.-X., Wei, X.-P., Li, K., Hua, F., Cui, B., Zhang, X., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.06.014 · Cited by 87
A Staphylococcus pro-apoptotic peptide induces acute exacerbation of pulmonary fibrosis
D’Alessandro‐Gabazza, C. N., Kobayashi, T., Yasuma, T., Toda, M., Kim, H., Fujimoto, H., Hataji, O., Takeshita, A., Nishihama, K., Okano, T., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15344-3 · Cited by 90
Restless legs syndrome: An overview of pathophysiology, comorbidities and therapeutic approaches (Review)
Vlasie, A., Trifu, S. C., Lupuleac, C., Kohn, B., & Cristea, M. B. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.11108 · Cited by 84
The methyl-CpG-binding domain 2 facilitates pulmonary fibrosis by orchestrating fibroblast to myofibroblast differentiation
Wang, Y., Zhang, L., Huang, T., Wu, G., Zhou, Q., Wang, F., Chen, L., Sun, F., Lv, Y., Xiong, F., et al. (2022) · European Respiratory Journal · doi:10.1183/13993003.03697-2020 · Cited by 84
The microbiome: an integral player in immune homeostasis and inflammation in the respiratory tract
Perdijk, O., Azzoni, R., & Marsland, B. J. (2023) · Physiological Reviews · doi:10.1152/physrev.00020.2023 · Cited by 94
Reactive oxygen species-evoked endoplasmic reticulum stress mediates 1-nitropyrene-induced epithelial-mesenchymal transition and pulmonary fibrosis
Fu, L., Zhao, H., Xiang, Y., Xiang, H.-X., Hu, B., Tan, Z.-X., Lu, X., Gao, L., Wang, B., Wang, H., et al. (2021) · Environmental Pollution · doi:10.1016/j.envpol.2021.117134 · Cited by 82
Role of Platelet-Derived Transforming Growth Factor-β1 and Reactive Oxygen Species in Radiation-Induced Organ Fibrosis
Ahamed, J., & Laurence, J. C. (2017) · Antioxidants and Redox Signaling · doi:10.1089/ars.2017.7064 · Cited by 84
Regulatory Immune Cells in Idiopathic Pulmonary Fibrosis: Friends or Foes?
van Geffen, C., Deißler, A., Quante, M., Renz, H. E., Hartl, D., & Kolahian, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.663203 · Cited by 82
Irreversibility of Pulmonary Fibrosis
Yu, Q. Y., & Tang, X. X. (2022) · Aging and Disease · doi:10.14336/ad.2021.0730 · Cited by 83
Imaging research in fibrotic lung disease; applying deep learning to unsolved problems
Walsh, S. L. F., Humphries, S. M., Wells, A. U., & Brown, K. K. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30003-5 · Cited by 82
Vitamin D and its therapeutic relevance in pulmonary diseases
Ahmad, S., Arora, S., Khan, S. F., Mohsin, M., Mohan, A., Manda, K., & Syed, M. A. (2020) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2020.108571 · Cited by 89
The Role of Nrf2 in Pulmonary Fibrosis: Molecular Mechanisms and Treatment Approaches
Wang, Y., Wei, J., Deng, H., Zheng, L., Yang, H. Y., & Lv, X. (2022) · Antioxidants · doi:10.3390/antiox11091685 · Cited by 80
Pulmonary fibrosis model of mice induced by different administration methods of bleomycin
Gul, A., Yang, F., Xie, C. H., Du, W., Mohammadtursun, N., Wang, B., Le, J., & Dong, J. (2023) · BMC Pulmonary Medicine · doi:10.1186/s12890-023-02349-z · Cited by 79
Targeting Fibrosis: From Molecular Mechanisms to Advanced Therapies
Di, X., Li, Y., Wei, J., Li, T., & Liao, B. (2024) · Advanced Science · doi:10.1002/advs.202410416 · Cited by 92
Src family kinases and pulmonary fibrosis: A review
Li, H., Zhao, C., Tian, Y., Lü, J., Zhang, G., Liang, S., Chen, D., Liu, X., Kuang, W., & Zhu, M. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110183 · Cited by 76
Mesenchymal stem cell‐derived extracellular vesicles suppress the fibroblast proliferation by downregulating FZD6 expression in fibroblasts via micrRNA‐29b‐3p in idiopathic pulmonary fibrosis
Wan, X., Chen, S., Yan, F., Zuo, W., Cui, J., & Xie, S. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29706 · Cited by 78
p53: A Key Protein That Regulates Pulmonary Fibrosis
Wu, Q., Zhang, K., Jiang, S., Fu, L., Shi, Y., Tan, R., Cui, J., & Zhou, Y. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/6635794 · Cited by 78
The impact of formaldehyde exposure on lung inflammatory disorders: Insights into asthma, bronchitis, and pulmonary fibrosis
Bhat, A. A., Afzal, M., Goyal, A., Gupta, G., Thapa, R., Almalki, W. H., Kazmi, I. A., Alzarea, S. I., Shahwan, M. J., Paudel, K. R., et al. (2024) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2024.111002 · Cited by 83
“Velcro-type” crackles predict specific radiologic features of fibrotic interstitial lung disease
Sgalla, G., Walsh, S. L. F., Sverzellati, N., Fletcher, S., Cerri, S., Dimitrov, B., Nikolic, D., Barney, A., Pancaldi, F., Larcher, L., et al. (2018) · BMC Pulmonary Medicine · doi:10.1186/s12890-018-0670-0 · Cited by 76
Self-citation
Introducing variability in targeting the microtubules: Review of current mechanisms and future directions in colchicine therapy
Forkosh, E., Kenig, A., & Ilan, Y. (2020) · Pharmacology Research & Perspectives · doi:10.1002/prp2.616 · Cited by 79
Molecular Biomarkers in Idiopathic Pulmonary Fibrosis: State of the Art and Future Directions
Stainer, A., Faverio, P., Busnelli, S., Catalano, M., Zoppa, M. D., Marruchella, A., Pesci, A., & Luppi, F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126255 · Cited by 80
Tartrate-resistant acid phosphatase 5 promotes pulmonary fibrosis by modulating β-catenin signaling
Hu, Y., Wang, Q., Yu, J., Zhou, Q., Deng, Y., Liu, J., Zhang, L., Xu, Y., Xiong, W., & Wang, Y. (2022) · Nature Communications · doi:10.1038/s41467-021-27684-9 · Cited by 76
Association between genetically determined telomere length and health‐related outcomes: A systematic review and meta‐analysis of Mendelian randomization studies
Chen, B., Yan, Y., Wang, H., & Xu, J. (2023) · Aging Cell · doi:10.1111/acel.13874 · Cited by 78
Exosome-Derived microRNA-22 Ameliorates Pulmonary Fibrosis by Regulating Fibroblast-to-Myofibroblast Differentiation in Vitro and in Vivo
Kuse, N., Kamio, K., Azuma, A., Matsuda, K., Inomata, M., Usuki, J., Morinaga, A., Tanaka, T., Kashiwada, T., Atsumi, K., et al. (2019) · Journal of Nippon Medical School · doi:10.1272/jnms.jnms.2020_87-302 · Cited by 75
Nutrition in Patients with Idiopathic Pulmonary Fibrosis: Critical Issues Analysis and Future Research Directions
Faverio, P., Bocchino, M., Caminati, A., Fumagalli, A., Gasbarra, M., Iovino, P., Petruzzi, A., Scalfi, L., Sebastiani, A., Stanziola, A. A., et al. (2020) · Nutrients · doi:10.3390/nu12041131 · Cited by 76
Pulmonary fibrosis from molecular mechanisms to therapeutic interventions: lessons from post-COVID-19 patients
Giacomelli, C., Piccarducci, R., Marchetti, L., Romei, C., & Martini, C. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114812 · Cited by 77
Diagnostic Likelihood Thresholds That Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis
Walsh, S. L. F., Lederer, D. J., Ryerson, C. J., Kolb, M. R. J., Maher, T. M., Nusser, R., Poletti, V. E., Richeldi, L., Vancheri, C., WILSHER, M. L., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201903-0493oc · Cited by 73
Self-citation
Role of Lung Microbiome in Innate Immune Response Associated With Chronic Lung Diseases
Paudel, K. R., Dharwal, V., Patel, V. K., Galvão, I., Wadhwa, R., Malyla, V., Shen, S., Budden, K. F., Hansbro, N. G., Vaughan, A., et al. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00554 · Cited by 75
Quercetin ameliorates pulmonary fibrosis by inhibiting SphK1/S1P signaling
Zhang, X., Cai, Y., Zhang, W., & Chen, X. (2018) · Biochemistry and Cell Biology · doi:10.1139/bcb-2017-0302 · Cited by 73
The Management of Patients With Idiopathic Pulmonary Fibrosis
Spagnolo, P., Τzouvelekis, Α., & Bonella, F. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00148 · Cited by 74
Health-related quality of life of patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis
Cox, I. A., Arriagada, N. B., de Graaff, B., Corte, T. J., Glaspole, I., Lartey, S. T., Walters, E. H., & Palmer, A. J. (2020) · European Respiratory Review · doi:10.1183/16000617.0154-2020 · Cited by 80
Baseline characteristics and survival of patients of idiopathic pulmonary fibrosis: a longitudinal analysis of the Swedish IPF Registry
Gao, J., Kalafatis, D., Carlson, L., Pesonen, I., Li, C., Wheelock, Å. M., Magnusson, J. M., & Sköld, C. M. (2021) · Respiratory Research · doi:10.1186/s12931-021-01634-x · Cited by 72
The Roles of Dipeptidyl Peptidase 4 (DPP4) and DPP4 Inhibitors in Different Lung Diseases: New Evidence
Zhang, T., Tong, X., Zhang, S., Wang, D., Wang, L., Wang, Q., & Fan, H. S. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.731453 · Cited by 73
Pseudohypoxic HIF pathway activation dysregulates collagen structure-function in human lung fibrosis
Brereton, C. J., Yao, L., Davies, E. R., Zhou, Y., Vukmirovic, M., Bell, J. A., Wang, S., Ridley, R. A., Dean, L. S. N., Andriotis, O. G., et al. (2022) · eLife · doi:10.7554/elife.69348 · Cited by 78
Self-citation
SPP1 promotes the polarization of M2 macrophages through the Jak2/Stat3 signaling pathway and accelerates the progression of idiopathic pulmonary fibrosis
Yang, X., Liu, Z., Zhou, J., Guo, J., Han, T., Liu, Y., Li, Y., Bai, Y., Xing, Y., Wu, J., et al. (2024) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2024.5413 · Cited by 71
The fibrogenic actions of the coagulant and plasminogen activation systems in pulmonary fibrosis
Schuliga, M. J., Grainge, C., Westall, G. P., & Knight, D. A. (2018) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2018.02.016 · Cited by 71
Interleukin-18 promotes fibroblast senescence in pulmonary fibrosis through down-regulating Klotho expression.
Zhang, L.-M., Zhang, J., Zhang, Y., Fei, C., Wang, L., Yi, Z., & Zhang, Z.-Q. (2019) · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · doi:10.1016/j.biopha.2019.108756 · Cited by 67
Trajectory modeling of endothelial-to-mesenchymal transition reveals galectin-3 as a mediator in pulmonary fibrosis
Jia, W., Wang, Z., Gao, C., Wu, J., & Wu, Q. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03603-0 · Cited by 68
Plasma cell but not CD20-mediated B-cell depletion protects from bleomycin-induced lung fibrosis
Prêle, C. M., Miles, T., Pearce, D. R., O’Donoghue, R. J. J., Grainge, C., Barrett, L. W., Birnie, K. A., Lucas, A., Baltic, S., Ernst, M., et al. (2022) · European Respiratory Journal · doi:10.1183/13993003.01469-2021 · Cited by 69
The emerging roles of interstitial macrophages in pulmonary fibrosis: A perspective from scRNA-seq analyses
Gu, Y., Lawrence, T., Mohamed, R., Liang, Y., & Yahaya, B. H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.923235 · Cited by 73
Endocrine and metabolic factors and the risk of idiopathic pulmonary fibrosis: a Mendelian randomization study
Jiang, Y., Chen, R., Xu, S., Ding, Y., Zhang, M., Bao, M., He, B., & Li, S. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1321576 · Cited by 70
Breathlessness and Restrictive Lung Disease: An Important Diabetes-Related Feature in Patients with Type 2 Diabetes
Kopf, S., Groener, J. B., Κender, Ζ., Fleming, T., Brune, M., Riedinger, C., Volk, N., Herpel, E., Pesta, D. H., Szendrödi, J., et al. (2018) · Respiration · doi:10.1159/000488909 · Cited by 66
Inhaled pirfenidone solution (AP01) for IPF: a randomised, open-label, dose–response trial
West, A., Chaudhuri, N., Barczyk, A., Wilsher, M. L., Hopkins, P., Glaspole, I., Corte, T. J., Šterclová, M., Veale, A., Jassem, E., et al. (2023) · Thorax · doi:10.1136/thorax-2022-219391 · Cited by 67
Alveolar epithelial cell‐derived Sonic hedgehog promotes pulmonary fibrosis through OPN‐dependent alternative macrophage activation
Hou, J., Ji, J., Chen, X., Cao, H., Tan, Y., Cui, Y., Xiang, Z., & Han, X. (2020) · FEBS Journal · doi:10.1111/febs.15669 · Cited by 66
The role of natural products in the prevention and treatment of pulmonary fibrosis: a review
Wang, L., Li, S., Yao, Y., Yin, W., & Ye, T. (2020) · Food & Function · doi:10.1039/d0fo03001e · Cited by 67
Autophagy and Renal Fibrosis
Liang, S., Wu, Y.-S., Li, D.-Y., Tang, J., & Liu, H. (2022) · Aging and Disease · doi:10.14336/ad.2021.1027 · Cited by 68
Human Lung Organoids—A Novel Experimental and Precision Medicine Approach
Kühl, L., Graichen, P., von Daacke, N., Mende, A., Wygrecka, M., Potaczek, D. P., Miethe, S., & Garn, H. (2023) · Cells · doi:10.3390/cells12162067 · Cited by 67
Targeting GPCR Signaling for Idiopathic Pulmonary Fibrosis Therapies
Haak, A. J., Ducharme, M. T., Espinosa, A. M. D., & Tschumperlin, D. J. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.12.008 · Cited by 69
Hyperoside Attenuates Bleomycin-Induced Pulmonary Fibrosis Development in Mice
Huang, J., Tong, X., Zhang, L., Zhang, Y., Wang, L., Wang, D., Zhang, S., & Fan, H. S. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.550955 · Cited by 66
Stem cell-based therapy for pulmonary fibrosis
Cheng, W., Zeng, Y., & Wang, D. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-03181-8 · Cited by 65
Pulmonary Rehabilitation for Exercise Tolerance and Quality of Life in IPF Patients: A Systematic Review and Meta-Analysis
Yu, X., Li, X., Wang, L., Liu, R., Xie, Y., Li, S., & Li, J. (2019) · BioMed Research International · doi:10.1155/2019/8498603 · Cited by 70
Inhalation of Tetrandrine-hydroxypropyl-β-cyclodextrin Inclusion Complexes for Pulmonary Fibrosis Treatment
Su, W., Liang, Y., Meng, Z., Chen, X., Lu, M., Han, X., Deng, X., Zhang, Q., Zhu, H., & Fu, T. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00026 · Cited by 68
Exosomal let-7i-5p from three-dimensional cultured human umbilical cord mesenchymal stem cells inhibits fibroblast activation in silicosis through targeting TGFBR1
Xu, C., Hou, L., Zhao, J., Wang, Y., Jiang, F., Jiang, Q., Zhu, Z., & Tian, L. (2022) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2022.113302 · Cited by 65
Targeting Histone Deacetylases in Idiopathic Pulmonary Fibrosis: A Future Therapeutic Option
Korfei, M., Mahavadi, P., & Guenther, A. (2022) · Cells · doi:10.3390/cells11101626 · Cited by 66
PIEZO1 mediates periostin+ myofibroblast activation and pulmonary fibrosis in mice
Xu, L., Li, T., Cao, Y., He, Y., Shao, Z., Liu, S., Wang, B., Su, A., Tian, H., Li, Y., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci184158 · Cited by 73
Potential regulatory role of circular RNA in idiopathic pulmonary fibrosis
Li, R., Wang, Y., Song, X., Sun, W., Zhang, J., Liu, Y., Li, H., Meng, C., Zhang, J., Zheng, Q., et al. (2018) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2018.3892 · Cited by 65
Fibrotic Idiopathic Interstitial Lung Disease: The Molecular and Cellular Key Players
Samarelli, A. V., Tonelli, R., Marchioni, A., Bruzzi, G., Gozzi, F., Andrisani, D., Castaniere, I., Manicardi, L., Moretti, A., Tabbì, L., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168952 · Cited by 65
S100A12 as Biomarker of Disease Severity and Prognosis in Patients With Idiopathic Pulmonary Fibrosis
Li, Y., He, Y., Chen, S., Wang, Q., Yang, Y., Shen, D., Ma, J., Wen, Z., Ning, S., & Chen, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.810338 · Cited by 65
Artesunate: A review of its therapeutic insights in respiratory diseases
Zhang, J., Li, Y., Wan, J., Zhang, M., Li, C., & Lin, J. (2022) · Phytomedicine · doi:10.1016/j.phymed.2022.154259 · Cited by 64
Targeting Senescent Alveolar Epithelial Cells Using Engineered Mesenchymal Stem Cell-Derived Extracellular Vesicles To Treat Pulmonary Fibrosis
Long, Y., Yang, B., Lei, Q., Gao, F., Chen, L., Chen, W., Chen, S., Ren, W., Cao, Y., Xu, L., et al. (2024) · ACS Nano · doi:10.1021/acsnano.3c10547 · Cited by 65
Tanshinone IIA Activates Nuclear Factor-Erythroid 2-Related Factor 2 to Restrain Pulmonary Fibrosis via Regulation of Redox Homeostasis and Glutaminolysis
An, L., Peng, L., Sun, N.-Y., Yang, Y., Zhang, X., Li, B., Liu, B., Li, P., & Chen, J. (2018) · Antioxidants and Redox Signaling · doi:10.1089/ars.2018.7569 · Cited by 63
Epithelial–Mesenchymal Transition: A Major Pathogenic Driver in Idiopathic Pulmonary Fibrosis?
Salton, F., Ruaro, B., Confalonieri, P., & Confalonieri, M. (2020) · Medicina · doi:10.3390/medicina56110608 · Cited by 64
New insights into the Hippo/YAP pathway in idiopathic pulmonary fibrosis
Sun, M., Sun, Y., Feng, Z., Kang, X., Yang, W., Wang, Y., & Luo, Y. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105635 · Cited by 67
Lung repair and regeneration: Advanced models and insights into human disease
Basil, M. C., Alysandratos, K., Kotton, D. N., & Morrisey, E. E. (2024) · Cell stem cell · doi:10.1016/j.stem.2024.02.009 · Cited by 65
Matrisome Properties of Scaffolds Direct Fibroblasts in Idiopathic Pulmonary Fibrosis
Elowsson, L., Löfdahl, A., Åhrman, E., Müller, C., Notermans, T., Michaliková, B., Rosmark, O., Zhou, X.-H., Dellgren, G., Silverborn, M., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20164013 · Cited by 64
Targeted immunotherapy rescues pulmonary fibrosis by reducing activated fibroblasts and regulating alveolar cell profile
Yan, J., Wang, S.-Y., Su, Q., Zou, M.-W., Zhou, Z.-Y., Shou, J., & Huo, Y. (2025) · Nature Communications · doi:10.1038/s41467-025-59093-7 · Cited by 62
Evaluation of Correlations between Genetic Variants and High-Resolution Computed Tomography Patterns in Idiopathic Pulmonary Fibrosis
Baratella, E., Ruaro, B., Giudici, F., WADE, B. E., Santagiuliana, M., Salton, F., Confalonieri, P., Simbolo, M., Scarpa, A., Tollot, S., et al. (2021) · Diagnostics · doi:10.3390/diagnostics11050762 · Cited by 63
Harnessing the Role of HDAC6 in Idiopathic Pulmonary Fibrosis: Design, Synthesis, Structural Analysis, and Biological Evaluation of Potent Inhibitors
Campiani, G., Cavella, C., Osko, J. D., Brindisi, M., Relitti, N., Brogi, S., Saraswati, A. P., Federico, S., Chemi, G., Maramai, S., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00184 · Cited by 63
Fatty Acid Metabolism and Idiopathic Pulmonary Fibrosis
Geng, J., Liu, Y., Dai, H., & Wang, C. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2021.794629 · Cited by 61
CD147 contributes to SARS-CoV-2-induced pulmonary fibrosis
Wu, J., Chen, L., Qin, C., Huo, F., Liang, X., Yang, X., Zhang, K., Lin, P., Liu, J., Feng, Z., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01230-5 · Cited by 65
Realveolarization with inhalable mucus-penetrating lipid nanoparticles for the treatment of pulmonary fibrosis in mice
Wang, Y. X., Zhang, J., Liu, Y., Xiao, Y., Han, K. S., Kong, Z., Dong, Y., Yang, Z., Fu, Z., Tang, C., et al. (2024) · Science Advances · doi:10.1126/sciadv.ado4791 · Cited by 68
MicroRNA-29b Mediates Lung Mesenchymal-Epithelial Transition and Prevents Lung Fibrosis in the Silicosis Model
Sun, J., Li, Q., Lian, X., Zhu, Z., Chen, X., Pei, W., Li, S., Abbas, A., Wang, Y., & Tian, L. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.10.017 · Cited by 62
Randomised, double-blind, placebo-controlled pilot trial of omeprazole in idiopathic pulmonary fibrosis
Dutta, P., Funston, W., Mossop, H., Ryan, V., Jones, R., Forbes, R., Sen, S., Pearson, J. P., Griffin, S. M., Smith, J. A., et al. (2019) · Thorax · doi:10.1136/thoraxjnl-2018-212102 · Cited by 65

Authors: Richeldi, L., Collard, H. R., & Jones, M. G.
Affiliations: Università Cattolica del Sacro Cuore (IT)
University of California, San Francisco (US)
National Institute for Health and Care Research (GB)
Corresponding author: Richeldi, Luca
ORCID: Richeldi, Luca
Collard, Harold R
Jones, Mark G
Venue: The Lancet
Publisher: Elsevier BV
Published: 2017-05
Volume: 389
Issue: 10082
Pages: 1941-1952
ISSN: 0099-5355 (ISSN-L)
0140-6736
DOI: 10.1016/s0140-6736(17)30866-8
OpenAlex: W2599075603
Cited by: 2,020
References: 143
Citations by year: 2026: 202 · 2025: 317 · 2024: 338 · 2023: 293 · 2022: 273 · 2021: 233 · 2020: 167 · 2019: 94 · 2018: 76 · 2017: 22
FWCI: 17.97
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: The Lancet (publishedVersion)
PubMed (publishedVersion)
ePrints Soton (University of Southampton) (acceptedVersion)
Funders: National Institute for Health and Care Research (CL-2016-26-004)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
Keywords: idiopathic pulmonary fibrosis, pulmonary fibrosis, pathophysiology, extracellular matrix, alveolar architecture, disease-modifying therapy, diagnosis, treatment options, respiratory failure
MeSH terms: Humans, Idiopathic Pulmonary Fibrosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Idiopathic pulmonary fibrosis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks